Chemistry:2-Fluoromethcathinone

From HandWiki

2-Fluoromethcathinone (2-FMC), also known as 2-flephedrone, is a psychostimulant and designer drug of the cathinone family.[1][2][3][4] It acts as a dopamine and norepinephrine releasing agent (NDRA).[4]

Pharmacology

The drug has an EC50 for dopamine release of 48.7 nM and induces 85% release of norepinephrine at a concentration of 10 μM.[4] For comparison, the EC50 values of methcathinone are 49.9 nM for dopamine release and 22.4 nM for norepinephrine release and it induces 100% release of norepinephrine at a concentration of 10 μM.[4][5] Hence, compared to methcathinone, 2-FMC appears to be relatively more selective or efficacious for induction of dopamine release over norepinephrine release.[4][5] It is notable in this regard that selective dopamine releasing agents are largely unknown.[6][4]

See also

References

  1. "Cathinone derivatives: a review of their chemistry, pharmacology and toxicology". Drug Test Anal 3 (7–8): 439–453. 2011. doi:10.1002/dta.313. PMID 21755607. 
  2. "Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Adv Pharmacol. 69. 2014. pp. 581–620. doi:10.1016/B978-0-12-420118-7.00015-9. ISBN 978-0-12-420118-7. 
  3. "An Overview of New Psychoactive Substances and the Outlets Supplying them". Reports. 30 June 2011. doi:10.21427/43F1-XR91. https://arrow.tudublin.ie/cserrep/23/. Retrieved 24 November 2024. 
  4. 4.0 4.1 4.2 4.3 4.4 4.5 "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology (Berl) 236 (3): 915–924. March 2019. doi:10.1007/s00213-018-5063-9. PMID 30341459. 
  5. 5.0 5.1 "Dopamine-releasing agents". Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. July 2008. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. https://bitnest.netfirms.com/external/Books/Dopamine-releasing-agents_c11.pdf. 
  6. "Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys". J Pharmacol Exp Ther 320 (2): 627–636. February 2007. doi:10.1124/jpet.106.107383. PMID 17071819.